SULFASALAZINE DELAYED RELEASE 500mg. IP

An anti-inflammatory drug is indicated for the treatment of chronic inflammatory diseases such as rheumatoid arthritis in children and adults and ulcerative colitis. A highly effective anti-inflammatory agent that treats inflammatory bowel disease and several rheumatological disorders. (Leonard G Quallich, 2001) A safe and useful therapeutic modality in patients with chronic reactive arthritis or ankylosing spondylitis. (S H Zwillich, 1988) Demonstrates effectiveness in the long-term treatment of ulcerative colitis and Crohn's disease. (K M Das, 1976) Provides a statistically significant benefit in reducing the erythrocyte sedimentation rate and easing spinal stiffness in ankylosing spondylitis. (Junmin Chen, 2014) Has established therapeutic efficacy in treating mild to moderate chronic inflammatory bowel diseases such as ulcerative colitis and Crohn's disease affecting the colon. (Nielsen, 1982) An effective and safe drug capable of producing remissions in active rheumatoid arthritis. (V C Neumann, 1983) Provides a quicker onset of action compared to alternative DMARDs and decelerates the radiological advancement of rheumatoid arthritis. (C P Rains, 1995) An effective and safe drug in treating children with oligoarticular- and polyarticular-onset juvenile chronic arthritis. (M A van Rossum, 1998)